Draper, based in Cambridge, Massachusetts, signed a tissue model development deal with Bristol-Myers Squibb Company (NYSE:BMY). The companies will collaborate on developing a unique liver tissue model to screen drugs for toxicity. Draper will use its Human Organ Systems (HOS) platform to generate a liver model for Bristol-Myers Squibb to perform toxicity testing.
The stock Earnings per share (EPS) and the diluted EPS are the profitability measures used in the fundamental analysis of companies. The figure of EPS only takes into account a Bristol-Myers Squibb Company (NYSE:BMY) common shares, whereas the very important diluted EPS take into account all the convertible securities such as convertible bonds/convertible preferred stock, which are changed into equity or common stock. Dilutive effects occur when the number of shares increases, for example, through a new issue. If a company issues more shares to shareholders and other investors, this increases the number of shares outstanding and decreases the company’s earnings per share. Ultimately, this can decrease the stock price. Bristol-Myers Squibb Company (NYSE:BMY) Diluted EPS is 3.16, whereas the EPS Estimate for next year is 4.43. The Annual EPS Growth of past 5 years is 14.50% and Bristol-Myers Squibb Company (NYSE:BMY) yearly performance is -16.74% and net profit margin is 22.10%.
Key Performance indicators for Bristol-Myers Squibb Company (NYSE:BMY), in last 4 months the performance of BMY was -4.95% while its price to sale ratio is 3.18 and price to book ratio is 4.87. Company gross margin stands at 71.10% whereas its return on investment (ROI) is 25.40%.
On 28 June 2019, Bristol-Myers Squibb Company (NYSE:BMY), a Healthcare sector firm, traded 15.57 Million shares in last trading session and stock advanced 0.55% with closing price of $45.35 per share. with Bristol-Myers Squibb Company (NYSE:BMY) traded 15.57 Million shares. The BMY distance from 20 day simple moving average is -3.24% and distance from 50-Day simple moving average is -2.78%.The relative strength index for stock is 42.15 and Average true range of BMY is 1.05.
Analyst’s mean target price for BMY is $55.56 while analysts mean recommendation is 2.30. The Stock value has moved between $44.46 – 63.87 in last one year. BMY market capitalization is 74101.90 with beta of 0.70. Company has 0.10% insider ownership.
Bristol-Myers Squibb Company (NYSE:BMY) is under coverage by number of analysts. Stock has got OUTPERFORM rating from 2 of Thomson Reuters analysts, 7 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Buy rating has been given by 3 analysts to the company stock.
